Đang chuẩn bị liên kết để tải về tài liệu:
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy. |

TÀI LIỆU LIÊN QUAN

Study of the drying on the pore network in order to comparison of the phase distribution between measured and simulated results

Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: Update on a phase II study

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Experimental results of gaslift process

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

Báo cáo khoa học: "Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer"

Báo cáo khoa học: " Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dosevolume effects of pelvic radiotherapy"

Báo cáo khoa học: " Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study"

Báo cáo khoa học: "Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial"

Báo cáo khoa học: " Prospective phase II study of preoperative short-course radiotherapy for rectal cancer with twice daily fractions of 2.9 Gy to a total dose of 29 Gy - Long-term results"
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.